



6 January 2014

Australian Stock Exchange Limited
Level 6, Exchange Centre
20 Bridge Street
Sydney NSW 2000

COMPANY ANNOUNCEMENTS

OncoSil Medical Limited – OSL

Result of the Extraordinary General Meeting of Members – 6 January 2014

We advise that:

a) The following resolutions were passed on a show of hands at the Extraordinary General Meeting of OncoSil Medical Limited on Monday 6th January 2014.

Ordinary Business

Resolution 1 – Re-approval of Issue of Loan Shares to Dr Neil Frazer

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, in accordance with the ASX letter, Shareholders re-approve the issue of 20,000,000 Loan Shares to Dr Neil Frazer under the Company’s Employee Share Plan on the terms and conditions outlined in the Explanatory Statement which accompanies the Notice of Extraordinary General Meeting”.

Resolution 2 –Re-approval of Issue of Loan Shares to Martin Rogers

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, in accordance with the ASX Letter, Shareholders re-approve the issue of 5,000,000 Loan Shares to Mr Martin Rogers under the Company’s Employee Share Plan on the terms and conditions outlined in the Explanatory Statement which accompanied the Notice of Extraordinary Notice of Meeting.”

b) A summary of valid and eligible proxies received for the above meeting was as follows:

	Discretion	For	Against	Abstain
Resolution 1				
Re-approval of Issue of Loan Shares to Dr Neil Frazer	-	95,149,734	41,250	26,155,384
Resolution 2				
Re-approval of Issue of Loan shares to Mr Martin Rogers	-	111,065,952	41,250	10,197,916

Yours faithfully
OncoSil Medical Limited



Nicholas Falzon
Company Secretary

About OncoSil Medical Ltd

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical.

Pancreatic Cancer

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.